Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11723001 | 0.78 | HTT (0.42) | ALDH1A1MAPTHPGDKDM4ELMNA | |
| SCHEMBL4064642 | 0.75 | HSD17B10 (0.48) | ALDH1A1HSD17B10MAPTHPGDTP53 | |
| SCHEMBL28397946 | 0.75 | KDM4E (0.55) | ALDH1A1HSD17B10MAPTHPGDCYP1A2 | |
| SCHEMBL25302521 | 0.74 | FFAR1 (0.43) | ALDH1A1HPGDLMNATSHRMEN1 | |
| SCHEMBL2892679 | 0.73 | PDGFRB (0.47) | ALDH1A1MAPTPKMPDGFRBFGFR1 | |
| SCHEMBL4069316 | 0.73 | RECQL (0.43) | ALDH1A1HSD17B10MAPTHPGDTP53 | |
| SCHEMBL4070239 | 0.73 | HSD17B10 (0.46) | ALDH1A1HSD17B10MAPTHPGDPKM | |
| SCHEMBL4068543 | 0.72 | L3MBTL1 (0.33) | ALDH1A1HPGDCYP1A2CYP2C19KDM4E | |
| SCHEMBL838041 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HSD17B10MAPTHPGDTP53 | |
| SCHEMBL6627580 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HSD17B10MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-116981661-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2022184152-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-09-09 | — | — | WO | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | disclosed |
| EP-1706412-A4 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS CO LTD (KR) | 2009-03-18 | — | — | EP | disclosed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1706412-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK Chemicals, Co., Ltd. (KR) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063768-A1 | NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK CHEMICALS, CO., LTD. (KR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | IL5, IL1B, P2RY4 | ALDH1A1 1008/4885HSD17B10 3499/4885MAPT 1573/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | ALDH1A1 3571/4885HSD17B10 651/4885MAPT 4234/4885 |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | ALDH1A1 1835/4885HSD17B10 3453/4885MAPT 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.